{
  "trial_type": "LowerCourt",
  "date": {
    "era": "Heisei",
    "year": 20,
    "month": 10,
    "day": 14
  },
  "case_number": "平成15(行ウ)33",
  "case_name": "原子爆弾被爆者認定申請却下処分取消請求事件",
  "court_name": "千葉地方裁判所民事３部",
  "result": "その他",
  "gist": "被爆者の肝硬変等の疾病並びに陳旧性心筋梗塞及び脳梗塞後遺症の疾病につき，原子爆弾被爆者に対する援護に関する法律１１条１項に基づく原爆症認定の要件である放射線起因性が認められた事例",
  "lawsuit_id": "80005",
  "detail_page_link": "https://www.courts.go.jp/app/hanrei_jp/detail4?id=80005",
  "full_pdf_link": "https://www.courts.go.jp/app/files/hanrei_jp/005/080005_hanrei.pdf",
  "contents": "km\nSv\ncGy\ncGy\nSv\nkm\nkm\nkm\nkm\nkm\nkm\nkg\nDosimetry System 2002\nkt kt\nkt kt\nkt kt\nkt\nkt\nkt\nPurdue\n36Cl/Cl\nStraume\n36Cl/Cl\n36 36Cl/Cl Cl/Cl\nkm\nkm\nkm\nkm\nkm\nmGy\nkm km\nGy Gy Gy\nGy Gy\nkm\n2.1 2.5km 7.2 515 37 3.9 515 20\n2.6 3km 2.1 569 12 0.5 569 3\n3.1 4km 1.3 931 12 1.4 931 13\n4.1 5km 0.4 226 1 0.4 226 1\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\n1.5 2.0 234 6.4 17.5 16.6 20.9 8.1 3.4 2.1\n2.0 2.5 219 6.8 16.4 13.2 18.7 5.9 0.9 5.4\n2.5 3.0 236 3.3 10.1 8.8 14.8 2.5 2.1 2.9\n3.0 3.5 337 0.9 4.1 3.8 8.4 2.6 0.9 0.9\n3.5 4.0 200 1.0 3.5 3.5 4.0 2.0 1.0 3.0\n4.0 4.5 305 0 0 0.9 1.3 0 0.3 0\n5.0 117 0 0 0 1.7 0 0.8 0.8\nkm\n1.5 2.0 132 56.3 21.0 42.8 36.0 20.2 6.7 18.7\n2.0 2.5 91 53.8 26.3 35.1 23.0 10.9 6.5 10.9\n2.5 3.0 74 45.9 13.5 35.9 22.9 6.7 6.7 12.0\n3.0 3.5 95 18.9 7.3 8.4 12.6 7.3 0.2 0.1\n3.5 4.0 70 4.2 4.2 7.1 7.1 4.2 4.2 2.8\n4.0 4.5 74 0 0 2.7 0 1.3 0 0\n5.0 50 0 0 2.0 2.0 2.0 0 4.0\nkm\n1.5 2.0 108 6.5 33.0 23.1 33.3 12.9 4.6 12.9\n2.0 2.5 102 5.8 22.5 18.6 30.3 12.7 5.8 6.8\n2.5 3.0 174 4.0 17.8 20.1 28.7 9.7 7.4 8.6\n3.0 3.5 172 1.7 8.1 16.8 21.5 4.0 1.7 4.0\n3.5 4.0 111 0 4.5 11.7 11.7 2.7 0.9 1.8\n4.0 4.5 119 0.8 4.2 11.7 16.8 6.7 0 2.5\n5.0 76 1.3 2.6 22.3 19.7 14.4 3.9 5.2\nkm\n1.5 2.0 65 32.3 26.1 43.0 44.4 24.6 7.6 24.6\n2.0 2.5 40 30.0 10.0 5.0 30.0 10.0 0 7.5\n2.5 3.0 57 19.2 17.5 19.2 28.0 21.0 7.2 12.2\n3.0 3.5 65 13.9 9.2 23.0 24.6 12.3 4.6 7.6\n3.5 4.0 52 1.8 3.8 17.3 21.0 5.7 1.8 7.6\n4.0 4.5 32 0 3.1 12.4 18.7 9.3 3.1 9.3\n5.0 42 7.1 7.1 16.6 14.2 7.1 4.2 2.3\nkm\nkm km km\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nGy\nGy\nkm\nGy\nkm\nGy\ncGy\ncGy\nrad cGy\nrad cGy\ncGy\nMedical Internal Radiation Dose Committee\nmrad\ncGy mrad cGy\nrad\nrad rad\nrad\nrad\nrad\nrad\nBorg Conard\nrad\nrad Gy\nrad Gy\nkm\nkg\nmg\nmg mg\nGy Gy\nSv\nkm\nkm\nTybout\nWilson\nMcRaney\nPace Smith NavaI Medical Research Institute\nTybout\nPace\nNeher\n㎢mCi/\nm\nkm\nkm\nkm\nkm\nkm km\nkm\n㎢km\nkm\nkm\nmm\nmm\nkm mm\nkm\nmm\nkm\nkm\nkm\nkm\nrad\nmSv mSv\nmSv mSv\nm\nm\nGy\nBq Bq\nkg\nkg\nmTc-MDP\nmTc-MDP\nGy Gy\nGy\nBq\nBq\n㎠ Bq\n㎠ Bq\nℓ\ncm\nBq\nSv Sv\nmm cm\nGy Sv\nkg\nkg\nHei\nkg\nm\nSv\nSv\nkg\nm\nSv\nkg\nGy\nmGy\nD\nrad rad\nGy Gy\nmSv\ncGy cGy\nkm\n8 6 84 16.6 0 17.8 33.3 10.7 3.5 8.3\n8 7 214 35.0 0 39.3 39.3 7.4 2.8 3.2\n8 8 78 30.7 0 35.8 35.8 15.3 3.8 3.8\n8 9 17 0 0 5.8 29.4 11.7 0 5.8\n8 10 17 17.6 0 0 17.6 5.8 0 11.7\n8 11 6 16.7 0 50.0 33.3 33.3 0 0\n8 12 16 0 0 6.2 0 18.7 6.2 6.2\n8 13 7 14.2 0 14.2 0 0 0 0\n8 15 31 6.4 0 12.9 25.8 3.2 0 3.2\n8 20 26 11.5 0 3.8 11.5 3.8 0 3.8\n9 5 28 3.5 0 0 0 3.5 0 0\nkm\nkm\nrad rad rad\nrad\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nSv\ncGy cGy\nkm km\nkm\n㎢km\nAttributable Risk\nExcess Relative Risk\ndsage ageexp 30\nage\nSv\nexp\nLife Span Study\nAdult Health Study\nGy\nSposto\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nrad\nDarby\nrad\nSv\nSv\nSv\nSv\nSv\nkm\ncGy\ncGy\ncGy\ncGy\nGy\nGy\nkm\nkm cGy\nkm\nkm\ncGy\ncGy\ncGy\ncGy\nkm\nkm\nkm\nℓ\n-\nkIU ml kIU ml\nkm\nNone No\nSchreiber\nkm\nGy\nGy\nGy\nF Lennie\nWong\nGy\nDesmond E Thompson\nDesmond E Thompson\nSv\nSv\nSv\nGy Gy\nthe\ndifference was marginally significant\nDale L\nPreston\nSv\nSv\nSv\nSv\nSv\nSv\nSchreiber\nAsano\nPreston\nSharp\nOdds\nWong\nkm\ncGy\ncGy\ncGy\ncGy\nGy\nGy\nkm\nkm\ncGy\ncGy\ncGy\ncGy\ncGy\nkm\nGy\nGy\nkm\nkm\ncGy\ncGy\ncGy\ncGy\nGy\nGy\ncGy\nkm\nkm\ncGy\ncGy\ncGy\ncGy\ncGy\nkm\nrad\nSv\nSv\nkm\n.cr\n.cr\nℓ  ℓ ℓmmin g u\n.cr\n.cr\nkm\nkm\nkm\nkm\ncm\nkm\nrad\nrad rad rad\nGy\nGy\nGy Gy\nrad\nSv\nSv\nmSv\nSv\nSv\nSv\nSv\nkm\nkm\ncGy\ncGy\ncGy\ncGy\nGy\nGy\ncGy\ncGy\nkm\nkm\ncGy\ncGy\ncGy\ncGy\ncGy cGy cGy\nkm\nkm\nkm km\nkm\nBq\nCi\nGy\nrad cGy\nSv\nkm\nkm\nkm\ncm cal\nkm km\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm km\nkm\nkm\nGy\nGy\nkm km\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm km\nkm km\nkm\nkm\nGy\nkm\nkm\nkm\nGy Gy\nkm\nkm\nSv Sv\nStraume Ruehm\nkm\nkm\nCo\nkt\nkt kt\nkt\nkg\nkm\nkm\nPreeg\nkm\nkm\nkm\nkm\nkm\nkm rad\nkm\nkm\nkm km\nSr\nGy Gy\nkm\nGy\nGy\nmm cm\nCs\nCs\nCs\nCs\nrad\nGy rad Gy\nexp age\nexp\nage\nage\nexp exp\nSv\nSv\nGy\nGy\nkm\nLife Span Study\nAdult Health Study\nexp age\nGy\nSv Gy\nkm\nSv\nSv\nGy\nTotal Ig\netiological fraction\nAssigned share\nAttributable fraction\nkm\nkm km km\nGy\nSv\nkm km\nmarginaly significant 0.097\nkm\nkm\nSv\nGy\nℓ\nkm\nSv\nSv\nChramydia\npneumoniae\nkm\nkm\nkm\nkm\nkm\nkm\nkm\nkm\n13 823 14326\n14 9 6 15 5 6\n14 10 25 15 7 23\n14 813 15326\nkt\nkm\n36Cl/Cl\n60Co\nkm\nkm\nGy\nGy Gy\nGy\nGy\nGy\nGy\nGy\nkg\nkg\nkg\nkg\nkg kg\nGy Gy\nkm\nGy Gy\nGy Gy\nmg\nGy\nGy\nkm\nGy\ncGy\ncGy\nGy\nGy\n24 56Na Mn\nrad\nrad rad\nrad Gy rad Gy\nrad rad\ncm\nGy\nSv\nGy Gy\nGy\nGy\nkg\nkg\n-\nBq\n-Bq\npCi Kg\npCi Kg\npCi Kg pCi Kg\nGy\nGy\nSv\nGy\nCs\nGy\nGy\nmCi/km\ncm Bq\nMahara\nmCi/km cm Bq\nmCi/km\nMahara\nℓcm\nBq 3.3Bq/cm 10cm 10cm\nBq\n-Sv\n-10Sv Bq\n-Sv\n-Sv\nBq\n-Sv\n-Sv Bq\n-Sv\n-Sv\nBq\n.Sv\n-\n-Sv\nCi\nkg\nkg\nkg\nCi\nCi Ci\nGy\nGy\nGy\nkg\nkg\nGy\nkm\nkm\nGy\nGy\nGy\nGy\nGy\nGy\nGy\nGy Gy\nGy\nGy\nGy\nGy\nGy Gy\nkm\nkm\nkm\nkm\nkm\nkm\nkm km\nkm\nkm\nkm\nkm\nGy\nkm\nkm\ngraaf\nGy\nGy\nkm\nkm\nkm\nkm\nkm\nkm\nGy\nGy\nGy\nGy\nGy\nGy Gy\nGy\nGy\nSv\nGy\nGy\nkm\nkm\nGy\nkm km\nGy Gy\nGy\nGy\nkm\nGy\n1.\n2.\n1.\n3.\n1Sv\n1Sv\n4. Gy\n5.\n1.\n2.\nGy\nHCV\nHCV\nHCV\n1.\n2.\n1.\nGy\nGy\n2.\nGy\n3.\n4.\nkm\nkm\nGy\nGy\nGy\nGy\nGy\nGy\nkm\nkm\nGy\nGy\nGy\nGy\nGy\nGy\nGy\nGy Gy\nGy\nGy\n"
}